Syros Pharmaceuticals, Inc. (SYRS)

Syros Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	58.28	139.53	167.47	92.3	173.98	41.44
Short-Term Investments	-	-	34.84	38.07	-	49.98
Cash & Short-Term Investments	58.28	139.53	202.3	130.37	173.98	91.42
Cash Growth	-48.07%	-31.03%	55.18%	-25.07%	90.32%	-8.29%
Receivables	-	-	1.69	2.98	2.33	20.16
Prepaid Expenses	5.66	5.45	7.39	3.24	2.24	2.65
Restricted Cash	-	-	-	-	-	0.29
Total Current Assets	63.93	144.98	211.39	136.59	178.56	114.51
Property, Plant & Equipment	17.58	19.48	24.66	27.29	29.64	31.89
Long-Term Investments	-	-	-	13.04	-	-
Other Long-Term Assets	3.49	3.71	8.43	6.03	5.05	3.58
Total Assets	85	168.17	244.49	182.94	213.25	149.98

Liabilities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Accounts Payable	9.65	11.54	6.41	3.69	3.6	5.85
Accrued Expenses	16.16	16.15	17.97	15.62	11.08	10.65
Current Portion of Long-Term Debt	-	6.67	-	-	-	-
Current Portion of Leases	2.58	2.32	2.07	2.01	1.73	1.28
Current Unearned Revenue	-	-	4.33	10.18	12.21	5.74
Total Current Liabilities	28.39	36.68	30.78	31.51	28.62	23.52
Long-Term Debt	41.08	34.56	40.65	40.26	39.55	-
Long-Term Leases	16.56	18.53	20.85	22.92	24.93	24.64
Long-Term Unearned Revenue	-	-	-	-	9.88	22.64
Other Long-Term Liabilities	10.08	61.75	24.47	3.03	19.71	-
Total Liabilities	96.12	151.51	116.75	97.72	122.7	70.79

Shareholders' Equity

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Common Stock	0.03	0.03	0.02	0.01	0.06	0.04
Additional Paid-In Capital	745.09	739.44	685.85	548.87	467.52	372.1
Retained Earnings	-756.24	-722.81	-558.23	-463.58	-377.02	-292.98
Comprehensive Income & Other	-	-	0.1	-0.08	-	0.02
Total Common Equity	-11.12	16.66	127.74	85.22	90.55	79.18
Shareholders' Equity	-11.12	16.66	127.74	85.22	90.55	79.18
Total Liabilities & Equity	85	168.17	244.49	182.94	213.25	149.98

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Total Debt	60.23	62.08	63.57	65.19	66.21	25.92
Net Cash (Debt)	-1.95	77.45	138.73	78.22	107.77	65.5
Net Cash Growth	-	-44.17%	77.37%	-27.42%	64.54%	-34.27%
Net Cash Per Share	-0.05	2.73	10.98	12.51	23.40	16.28
Filing Date Shares Outstanding	26.83	26.45	20.3	6.21	6.16	4.34
Total Common Shares Outstanding	26.83	26.45	20.26	6.2	5.62	4.34
Working Capital	35.54	108.3	180.61	105.08	149.93	91
Book Value Per Share	-0.41	0.63	6.30	13.74	16.11	18.26
Tangible Book Value	-11.12	16.66	127.74	85.22	90.55	79.18
Tangible Book Value Per Share	-0.41	0.63	6.30	13.74	16.11	18.26
Machinery	-	3.28	12.25	11.04	9.77	7.88
Construction In Progress	-	-	-	-	0.01	0.16
Leasehold Improvements	-	11.66	11.66	11.66	11.66	11.61

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 29, 2026

Data Sources Report a data error